VIPoma: an unsuspecting culprit of severe secretory diarrhoea in a human immunodeficiency virus-infected patient.
HIV
VIPoma
neuroendocrine tumour
pancreatic cholera
secretory diarrhoea
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
16
06
2021
received:
11
03
2021
accepted:
29
06
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
18
3
2022
Statut:
ppublish
Résumé
A 35-year-old man with known human immunodeficiency virus experienced chronic diarrhoea for 18 months. He presented to multiple hospitals with profuse secretory diarrhoea and life-threatening electrolyte disturbances. Infectious and non-infectious aetiologies were considered, with focussed history and investigations ultimately leading to a diagnosis of VIPoma. Initiation of somatostatin analogue therapy followed by surgical resection led to complete resolution of symptoms and markedly improved quality of life.
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-129Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Schiller LR, Pardi DS, Sellin JH. Chronic diarrhea: diagnosis and management. Clin Gastroenterol Hepatol 2017; 15: 182-93.e3.
Bloom SR. Clinical biochemical and pathological studies on 62 vipomas. Gastroenterology 1980; 78: 1143.
Iwasaki M, Akiba Y, Kaunitz JD. Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. F1000Research 2019; 8: 1629.
Ngwainmbi J, De DD, Smith TH, El-Hage N, Fitting S, Kang M et al. Effects of HIV-1 tat on enteric neuropathogenesis. J Neurosci 2014; 34: 14243-51.
Manfredi R, Vezzadini P, Costigliola P, Ricchi E, Fanti MP, Chiodo F. Elevated plasma levels of vasoactive intestinal peptide in AIDS patients with refractory idiopathic diarrhoea. Effects of treatment with octreotide. AIDS 1993; 7: 223-6.
Manfredi R, Vezzadini P, Fanti MP, Chiodo F. Vasoactive intestinal polypeptide (VIP) secretion and refractory diarrhea in patients with AIDS or AIDS-related complex (ARC). Scand J Infect Dis 1994; 26: 55-7.
Belei OA, Heredea ER, Boeriu E, Marcovici TM, Cerbu S, Mărginean O et al. Verner-Morrison syndrome. Literature review. Rom J Morphol Embryol 2017; 58: 371-6.
Farina DA, Krogh KM, Boike JR. Chronic diarrhea secondary to newly diagnosed VIPoma. Case Rep Gastroenterol 2019; 13: 225-9.
Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ. Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg 2008; 12: 382-93.
Mendes Filho O, Maués CAD, De Macedo FPPC, Monteiro SAC, Araújo EFC, Rodriguez JER et al. Neuroendocrine pancreatic tumor causing chronic diarrhea in young adult, a case report. AME Case Rep 2020; 4: 13.
Lito P, Pantanowitz L, Marotti J, Aboulafia DM, Campbell V, Bower M et al. Gastroenteropancreatic neuroendocrine tumors in patients with HIV infection: a trans-Atlantic series. Am J Med Sci 2009; 337: 1-4.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 514-23.
Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-13.
Iwasaki M, Tsuchida K, Jinnai H, Komatsubara T, Arisaka T, Tsunemi M et al. Multimodal treatment of vasoactive intestinal polypeptide-producing pancreatic neuroendocrine tumors with liver metastases. Intern Med 2017; 56: 517-22.
Sidéris L, Dubé P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist 2012; 17: 747.
Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-Guibert J, Pyronnet S et al. Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends Endocrinol Metabol 2014; 25: 115-27.
Rinke A, Muller H, Schade-Brittinger C, Klose K-J, Barth P, Wied M et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009; 27: 4656-63.
Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology 2017; 105: 245-54.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017; 376: 125-35.